321 related articles for article (PubMed ID: 28703316)
1. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
Sahasrabudhe V; Terra SG; Hickman A; Saur D; Shi H; O'Gorman M; Zhou Z; Cutler DL
J Clin Pharmacol; 2017 Nov; 57(11):1432-1443. PubMed ID: 28703316
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
3. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
Fediuk DJ; Nucci G; Dawra VK; Cutler DL; Amin NB; Terra SG; Boyd RA; Krishna R; Sahasrabudhe V
Clin Pharmacokinet; 2020 Aug; 59(8):949-965. PubMed ID: 32337660
[TBL] [Abstract][Full Text] [Related]
4. The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.
Jeong SI; Ban MS; Hwang JG; Park MK; Lim S; Kim S; Kwon SK; Kim Y; Cho JM; Na JJ; Huh W; Chung JY
Diabetes Obes Metab; 2024 Jul; 26(7):2588-2597. PubMed ID: 38618974
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
[TBL] [Abstract][Full Text] [Related]
6. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.
Hu J; Deng A; Zhao Y
Expert Opin Pharmacother; 2018 Nov; 19(16):1841-1847. PubMed ID: 30223693
[TBL] [Abstract][Full Text] [Related]
7. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Sarashina A; Ueki K; Sasaki T; Tanaka Y; Koiwai K; Sakamoto W; Woerle HJ; Salsali A; Broedl UC; Macha S
Clin Ther; 2014 Nov; 36(11):1606-15. PubMed ID: 25199997
[TBL] [Abstract][Full Text] [Related]
8. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
[TBL] [Abstract][Full Text] [Related]
10. Ertugliflozin for the treatment of type 2 diabetes.
Sharma R; Razdan K; Kuhad A; Kuhad A
Drugs Today (Barc); 2019 Mar; 55(3):167-175. PubMed ID: 30938372
[TBL] [Abstract][Full Text] [Related]
11. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
Liu J; Pong A; Gallo S; Darekar A; Terra SG
Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension.
Amin NB; Wang X; Mitchell JR; Lee DS; Nucci G; Rusnak JM
Diabetes Obes Metab; 2015 Aug; 17(8):805-8. PubMed ID: 25951755
[TBL] [Abstract][Full Text] [Related]
13. Ertugliflozin for treatment of patients with Type 2 diabetes mellitus.
Yang J
Expert Rev Clin Pharmacol; 2018 Aug; 11(8):747-753. PubMed ID: 30025475
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
Fediuk DJ; Zhou S; Dawra VK; Sahasrabudhe V; Sweeney K
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):696-706. PubMed ID: 33205593
[TBL] [Abstract][Full Text] [Related]
15. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
[TBL] [Abstract][Full Text] [Related]
16. Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes.
Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Barsotti E; Clerico A; Muscelli E
Diabetes Care; 2017 Jun; 40(6):771-776. PubMed ID: 28325783
[TBL] [Abstract][Full Text] [Related]
17. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
Dawra VK; Liang Y; Shi H; Bass A; Hickman A; Terra SG; Zhou S; Cutler D; Sahasrabudhe V
Int J Clin Pharmacol Ther; 2019 Apr; 57(4):207-216. PubMed ID: 30802200
[TBL] [Abstract][Full Text] [Related]
18. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
Cherney DZI; Heerspink HJL; Frederich R; Maldonado M; Liu J; Pong A; Xu ZJ; Patel S; Hickman A; Mancuso JP; Gantz I; Terra SG
Diabetologia; 2020 Jun; 63(6):1128-1140. PubMed ID: 32236732
[TBL] [Abstract][Full Text] [Related]
19. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
[TBL] [Abstract][Full Text] [Related]
20. Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.
Cherney DZI; Cosentino F; Dagogo-Jack S; McGuire DK; Pratley R; Frederich R; Maldonado M; Liu CC; Liu J; Pong A; Cannon CP;
Clin J Am Soc Nephrol; 2021 Sep; 16(9):1345-1354. PubMed ID: 34497110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]